Zealand Pharma reports successful phase I/IIa trial with ZP10 in type 2 diabetes patients

Zealand Pharma announces promising results from a study with its lead compound ZP10 in type 2 diabetic patients.

The double-blind, placebo-controlled study assessed the safety, tolerability and efficacy of ZP10 in 28 subjects with type 2 diabetes. Each subject received a single dose of ZP10 (1 to 40 μg) or placebo and ingested a glucose loaded meal 1 hour after dosing.

No safety issues were identified during the study and the data indicated that ZP10 was tolerated at doses up to 20 μg. There was a dose dependent lowering of plasma glucose concentrations following ZP10 administration compared to placebo. A near-maximum effect was seen at a dose level at which no side effects were observed. Additionally ZP10 was demonstrated to increase insulin secretion and reduce post-meal increases in glucagon concentration.

ZP10 is an analogue of Exendin-4, which acts on the GLP-1 receptor. The results of the study are very encouraging for the further development of the compound as a novel therapy for type 2 diabetes. 

Currently, Zealand is seeking a partner for further development of the compound.

Zealand Pharma is a Danish biopharmaceutical company focusing on discovery and development of innovative drugs, which significantly improve existing treatment. The focus of our research and development is intercellular communication and modification of peptides. The company, which is located close to Copenhagen, was established in 1998 and today employs 40 people. Since 1999 we have advanced 2 drug candidates from research to clinical development and 1 other drug candidate to pre-clinical development.

For further information please contact:

Eva Steiness,
President and CEO,
Zealand Pharma
Phone: +45 4328 1210
Email: est@zp.dk